Update notification · 30.10.2026
Supply shortage Germany: PANTOPRAZOL BASICS 20 mg magensaftresistente Tabletten – Update notification, 30.10.2026 · ENR LE2026003984
Affected country: Germany · Reported period: 02.04.2026 – 30.11.2026 · Active ingredient: Pantoprazol-Natrium-Sesquihydrat
Active ingredients
Notice context
A supply shortage has been recorded for PANTOPRAZOL BASICS 20 mg magensaftresistente Tabletten in Germany. The stated reason is “Production problem”. The notice concerns the active ingredient Pantoprazol-Natrium-Sesquihydrat and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Germany. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for PANTOPRAZOL BASICS 20 mg magensaftresistente Tabletten is a supply signal concerning Pantoprazol-Natrium-Sesquihydrat in Germany. The published reason “Production problem” determines which data should be verified first.
For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.
Once a lawful sourcing route is confirmed and buffer stock is required, our pharma warehouse in Cheb page explains receipt, stock control and picking.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
For manufacturing shortages, an agreed restart stock for PANTOPRAZOL BASICS 20 mg magensaftresistente Tabletten can be received and distributed under control after release.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.
Operational checks for this notice
- Match product identity using PZN 03275789, 05373763, 05454415, 10234058, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period 02.04.2026 to 30.11.2026 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving PANTOPRAZOL BASICS 20 mg magensaftresistente Tabletten: